Cargando…

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients

SIMPLE SUMMARY: The CD38-targeting antibody daratumumab has marked activity in multiple myeloma through direct anti-tumor effects and immunomodulatory activity. However, eventually most patients will develop daratumumab-refractory disease. We hypothesized that daratumumab-resistance could be reverse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frerichs, Kristine A., Verkleij, Christie P. M., Dimopoulos, Meletios A., Marin Soto, Jhon A., Zweegman, Sonja, Young, Mary H., Newhall, Kathryn J., Mutis, Tuna, van de Donk, Niels W. C. J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158123/ https://www.ncbi.nlm.nih.gov/pubmed/34070044 http://dx.doi.org/10.3390/cancers13102452

Ejemplares similares

CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients
por: Frerichs, Kristine A., et al.
Publicado: (2019)

Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma
por: Frerichs, Kristine A., et al.
Publicado: (2021)

Cytomegalovirus Reactivation in a Patient With Extensively Pretreated Multiple Myeloma During Daratumumab Treatment
por: Frerichs, Kristine A., et al.
Publicado: (2019)

NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma
por: Verkleij, Christie P.M., et al.
Publicado: (2023)

Cerebrospinal Fluid Penetrance of Daratumumab in Leptomeningeal Multiple Myeloma
por: Zajec, Marina, et al.
Publicado: (2020)

PB2132: EXCALIBER-RRMM: A PHASE 3, TWO-STAGE STUDY OF IBERDOMIDE, DARATUMUMAB, AND DEXAMETHASONE VERSUS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Lonial, Sagar, et al.
Publicado: (2023)

Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma
por: Hosny, Mashhour, et al.
Publicado: (2021)

Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies
por: Verkleij, Christie P. M., et al.
Publicado: (2020)

Trogocytosis represents a novel mechanism of action of daratumumab in multiple myeloma
por: Krejcik, Jakub, et al.
Publicado: (2018)

T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma
por: Verkleij, Christie P.M., et al.
Publicado: (2020)

Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study “REBUILD”
por: Terpos, Evangelos, et al.
Publicado: (2022)

Daratumumab for the Treatment of Multiple Myeloma
por: Plesner, Torben, et al.
Publicado: (2018)

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX
por: Kaufman, Jonathan L., et al.
Publicado: (2020)

Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
por: Gasparetto, Cristina, et al.
Publicado: (2020)

Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma
por: Afrough, Aimaz, et al.
Publicado: (2023)

Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
por: Yarlagadda, Lakshmi, et al.
Publicado: (2021)

Daratumumab in dialysis-dependent multiple myeloma
por: Jeyaraman, Preethi, et al.
Publicado: (2020)

Daratumumab efficacy in extramedullary orbital myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective Study
por: Terpos, Evangelos, et al.
Publicado: (2021)

Daratumumab monotherapy for refractory lupus nephritis
por: Roccatello, Dario, et al.
Publicado: (2023)

Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study
por: Suzuki, Kenshi, et al.
Publicado: (2018)

High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action
por: Adams, Homer C., et al.
Publicado: (2018)

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
por: Siegel, David S., et al.
Publicado: (2020)

Role of Daratumumab in Combination With Standard Therapies in Patients With Relapsed and Refractory Multiple Myeloma
por: Bapatla, Anusha, et al.
Publicado: (2021)

Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma
por: Sanchez, Larysa, et al.
Publicado: (2021)

Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
por: Moreau, Philippe, et al.
Publicado: (2023)

Potential role of daratumumab in the treatment of multiple myeloma
por: Khagi, Yulian, et al.
Publicado: (2014)

Daratumumab in untreated newly diagnosed multiple myeloma
por: Abdallah, Nadine, et al.
Publicado: (2019)

Optimizing the Outcome of Anti-Myeloma Treatment with Daratumumab
por: Plesner, Torben
Publicado: (2021)

Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome
por: Gavriatopoulou, Maria, et al.
Publicado: (2020)

Pharmacokinetics and Exposure–Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma
por: Xu, Xu Steven, et al.
Publicado: (2018)

Daratumumab: Dawn of a New Paradigm in Multiple Myeloma?
por: Kalis, Joseph A.
Publicado: (2017)

Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis
por: Theodorakakou, Foteini, et al.
Publicado: (2021)

Daratumumab for the treatment of refractory ANCA-associated vasculitis
por: Ostendorf, Lennard, et al.
Publicado: (2023)

Efficacy of daratumumab in refractory primary Sjögren disease
por: Nocturne, Gaetane, et al.
Publicado: (2023)

Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma
por: Usmani, Saad Z., et al.
Publicado: (2018)

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
por: Dimopoulos, Meletios A., et al.
Publicado: (2018)

Targeted Therapy With Immunoconjugates for Multiple Myeloma
por: Bruins, Wassilis S. C., et al.
Publicado: (2020)

Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
por: Offidani, Massimo, et al.
Publicado: (2021)

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma
por: Overdijk, Marije B, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_2l0qansqtqkc54crjefi7kut67